Skip to content
Index by category

Reproductive & Hormonal

Goserelin

Zoladex; goserelin acetate

1 min read · Updated July 27, 2026 · 3 references

Curated by PeptideInfo Wikilast reviewed how we verify

In brief · TL;DR
Approved medicine· US

An approved GnRH agonist delivered as a biodegradable subcutaneous implant.

Evidence: Regulator-approved drug with human trial evidence.

Approved in: FDA (United States; indication and strength depend on product label)

  • An approved GnRH agonist delivered as a biodegradable subcutaneous implant.
  • After a transient stimulation phase, sustained exposure down-regulates pituitary GnRH receptors and suppresses gonadal hormone production.
  • The label describes tumor flare, hot flushes, glucose and cardiovascular risks, QT prolongation, reduced bone density and injection-site injury; product strength and indication must not be interchanged.
↓ Read the full referenced entry below

An approved GnRH agonist delivered as a biodegradable subcutaneous implant.

Overview

An approved GnRH agonist delivered as a biodegradable subcutaneous implant.

Primary regulatory source

This is an educational reference, not individual medical advice. Use requires a prescriber and indication-specific monitoring.

Identity and mechanism

After a transient stimulation phase, sustained exposure down-regulates pituitary GnRH receptors and suppresses gonadal hormone production.

PubChem CID 5311128; C59H84N18O14; 1269.4 Da.

Regulatory label facts

FDA (United States; indication and strength depend on product label).

The dose below reproduces a regulator-approved label; it is not a treatment recommendation. The cited Zoladex label uses a 10.8 mg subcutaneous implant every 12 weeks for its listed prostate-cancer indications.

Safety boundary

The label describes tumor flare, hot flushes, glucose and cardiovascular risks, QT prolongation, reduced bone density and injection-site injury; product strength and indication must not be interchanged.

This is an educational reference, not individual medical advice. Use requires a prescriber and indication-specific monitoring.

References

  1. 1.
    Goserelin — Primary regulatory source source
  2. 2.
    Goserelin — PubChem compound record source
  3. 3.
    Goserelin — Human study source

Frequently asked questions

What is Goserelin?
An approved GnRH agonist delivered as a biodegradable subcutaneous implant.
Is Goserelin approved as a medicine, and where?
It is an approved prescription medicine, but where it is approved matters: FDA (United States; indication and strength depend on product label). It should only be used under medical supervision.
What is Goserelin studied for?
Goserelin is most often discussed in the context of approved peptide medicines — verification pilot. Being studied for an area does not mean it is proven or approved for it.
Does Goserelin have human clinical trials?
Yes. Goserelin has been studied in human clinical trials and is an approved medicine in at least some regions.

Educational disclaimer. This article summarizes published research for informational purposes and is not medical advice. Goserelin is an approved medicine within the stated approval scope (FDA (United States; indication and strength depend on product label)) and must only be used under medical supervision; research-grade or unprescribed material is not a lawful substitute. Consult a qualified healthcare professional before making health decisions.

Related in Reproductive & Hormonal